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2373although repaired CHD is clearly associated with the
development of arrhythmias such as atrial ﬂutter and
ventricular tachycardia, exercise does not appear to
contribute to the risk.
The level of sports participation recommended in-
cludes consideration of both the training and the
competitive aspects of the activity but must be individu-
alized to the particular patient, taking into account
the patient’s functional status and history of surgery.
Noninvasive testing, such as formal exercise testing,
Holter monitoring, echocardiography, and cardiac mag-
netic resonance imaging studies, is also often useful.
TYPES OF CONGENITAL DEFECTS
Simple Shunting Lesions (Atrial Septal Defect, Ventricular Septal
Defect, Patent Ductus Arteriosus), Treated and Untreated
Of the 8 most common subtypes of CHD, ventricular
septal defect (VSD; 34%), atrial septal defect (ASD; 13%),
and patent ductus arteriosus (PDA; 10%), respectively, are
the most common (2). With rare exceptions, patients with
hemodynamically insigniﬁcant CHD such as VSD, ASD,
and PDA may participate competitively in all sports.
There are no demonstrative data that children with he-
modynamically insigniﬁcant VSD (open or after closure),
ASD (open or after closure), or PDA (open or after closure)
require exercise limitations or that these lesions are
related to acknowledged episodes of sudden cardiac
death (SCD) (3,4). Patients with associated pulmonary
hypertension secondary to the above-mentioned lesions
that is hemodynamically signiﬁcant can develop acute
symptoms, including reduced exercise capacity or, more
importantly, arrhythmias, syncope, chest pain, or sudden
death (5,6). For the purposes of this document, pulmo-
nary hypertension is deﬁned as a mean pulmonary artery
pressure >25 mm Hg or a pulmonary vascular resistance
index of >3 Wood units.
Patients with right-to-left shunting may become
more cyanotic during exercise, at least in part because
of changes in the ratio of systemic vascular resistance
to pulmonary vascular resistance, which can result in
increased hypoxemia. Therefore, full clinical assess-
ment, including laboratory and exercise testing, should
be considered before any physical activity, because
this population represents a very high risk of sudden
death (6). Additional precautions should be taken
when these patients are exercising at altitude, because
the pulmonary vascular resistance generally rises,
thus increasing the degree of hypoxemia and cardiac
workload.
Children with open or surgically closed VSDs have
a normal exercise capacity despite a mild chronotropiclimitation in the latter. Some data suggest that aerobic
capacity is reduced in patients with open or closed VSDs,
as well as in patients with closed ASDs. Abnormal right
ventricular (RV) and pulmonary pressure can also occur
in those with isolated VSDs; however, these ﬁndings did
not impact these exercise recommendations or identify
any episodes of SCD (7).
ASD: Untreated
Recommendations
1. It is recommended that athletes with small defects
(<6 mm), normal right-sided heart volume, and no
pulmonary hypertension should be allowed to par-
ticipate in all sports (Class I; Level of Evidence C).
2. It is recommended that athletes with a large ASD
and no pulmonary hypertension should be allowed
to participate in all sports (Class I; Level of
Evidence C).
3. Athletes with an ASD and pulmonary hypertension
may be considered for participation in low-intensity
class IA sports (Class I; Level of Evidence C).
4. Athletes with associated pulmonary vascular
obstructive disease who have cyanosis and a large
right-to-left shunt should be restricted from partici-
pation in all competitive sports, with the possible
exception of class IA sports (Class III; Level of Evi-
dence C).ASD: After Surgical Repair or Closure by
Interventional Catheterization
Recommendations
1. Three to 6 months after operation or intervention,
athletes without pulmonary hypertension, myocardial
dysfunction, or arrhythmias may participate in all
sports (Class I; Level of Evidence C).
2. After operation or intervention, patients with pul-
monary hypertension, arrhythmias, or myocardial
dysfunction may be considered for participation in
low-intensity class IA sports (Class IIb; Level of
Evidence C).VSD: Untreated
Recommendations
1. An athlete with a small or restrictive VSD with normal
heart size and no pulmonary hypertension can
participate in all sports (Class I; Level of Evidence C).
2. An athlete with a large, hemodynamically signiﬁcant
VSD and pulmonary hypertension may consider
participation in only low-intensity class IA sports
(Class IIb; Level of Evidence C).
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2374VSD: After Surgical Repair or Closure by
Interventional Catheterization
Recommendations
1. At 3 to 6 months after repair, asymptomatic athletes
with no or a small residual defect and no evidence of
pulmonary hypertension, ventricular or atrial tachy-
arrhythmia, or myocardial dysfunction can participate
in all competitive sports (Class I; Level of Evidence C).
2. Athletes with persistent pulmonary hypertension
should be allowed to participate in class IA sports only
(Class I; Level of Evidence B).
3. Athletes with symptomatic atrial or ventricular tachy-
arrhythmias or second- or third-degree atrioventricular
block should not participate in competitive sports until
further evaluation by an electrophysiologist (Class III;
Level of Evidence C).
4. Athletes with mild to moderate pulmonary hyperten-
sion or ventricular dysfunction should not participate
in competitive sports, with the possible exception
of low-intensity class IA sports (Class III; Level of
Evidence C).PDA: Untreated
Recommendations
1. Athletes with a small PDA, normal pulmonary artery
pressure, and normal left-sided heart chamber dimen-
sion can participate in all competitive sports (Class I;
Level of Evidence C).
2. Athletes with a moderate or large PDA and persistent
pulmonary hypertension should be allowed to partici-
pate in class IA sports only (Class I; Level of Evidence B).
3. Athletes with a moderate or large PDA that causes left
ventricular (LV) enlargement should not participate in
competitive sports until surgical or interventional
catheterization closure (Class III; Level of Evidence C).PDA: Treated (After Surgical Repair or Closure by
Interventional Catheterization)
Recommendations
1. After recovery from catheter or surgical PDA closure,
athletes with no evidence of pulmonary hypertension
can participate in all competitive sports (Class I; Level
of Evidence C).
2. Athletes with residual pulmonary artery hypertension
should be restricted from participation in all compet-
itive sports, with the possible exception of class IA
sports (Class I; Level of Evidence B).Pulmonary Valve Stenosis: Treated and Untreated
Mild valvar pulmonary stenosis (PS) is characterized by
a systolic ejection murmur, a systolic ejection click thatvaries with respiration, and a normal ECG. Decisions
are based on estimated severity by use of Doppler-
derived peak instantaneous gradients. A gradient <40
mm Hg indicates mild PS, 40 to 60 mm Hg indicates
moderate PS, and >60 mm Hg indicates severe PS.
Treatment can be by surgery or more commonly
by balloon valvuloplasty. Adequate relief means a res-
olution of symptoms or a reduction in gradient to
<40 mm Hg.
Recommendations
1. Athletes with mild PS and normal RV function can
participate in all competitive sports. Annual reeval-
uation is also recommended (Class I; Level of Evi-
dence B).
2. Athletes treated by operation or balloon valvuloplasty
who have achieved adequate relief of PS (gradient
<40 mm Hg by Doppler) can participate in all com-
petitive sports (Class I; Level of Evidence B).
3. Athletes with moderate or severe PS can consider
participation only in low-intensity class IA and IB
sports (Class IIb; Level of Evidence B).
4. Athletes with severe pulmonary insufﬁciency as
demonstrated by marked RV enlargement can consider
participation in low-intensity class IA and IB sports
(Class IIb; Level of Evidence B).
Aortic Valve Stenosis: Treated and Untreated
Assessment of fully grown athletes with aortic stenosis
(AS) is discussed in the Task Force 5 report on valvular
heart disease (8). The following discussion pertains to
recommendations in children and adolescents. Patients
with AS are differentiated between those with mild,
moderate, and severe AS by physical examination, ECG,
and Doppler echocardiography. In all cases, regardless
of the degree of stenosis, patients with a history of fa-
tigue, light-headedness, dizziness, syncope, chest pain,
or pallor on exercise deserve a full evaluation. Annual
reevaluation is required for all patients with AS,
because the disease can progress. Patients with severe
AS are at risk of sudden death, particularly with exer-
cise (9).
Mild AS is deﬁned as a mean Doppler gradient of <25
mm Hg or a peak instantaneous Doppler gradient <40
mm Hg. On evaluation, patients should have a normal
ECG, normal exercise tolerance, and no history of
exercise-related chest pain, syncope, or atrial or ventric-
ular tachyarrhythmia. Moderate AS is deﬁned as a mean
Doppler gradient of 25 to 40 mm Hg or a peak instanta-
neous Doppler gradient of 40 to 70 mm Hg. Patients
should have only mild or no LV hypertrophy by echocar-
diogram and an absence of LV strain pattern on ECG, as
well as a normal maximum exercise stress test without
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2375evidence of ischemia or tachyarrhythmia, with normal
exercise duration and blood pressure response. Severe
AS is deﬁned as a mean Doppler gradient >40 mm Hg or a
peak instantaneous Doppler gradient >70 mm Hg. Such
patients may have symptoms such as exercise intoler-
ance, chest pain, near-syncope, or syncope and likely will
have LV hypertrophy with strain on ECG, as well as an
abnormal blood pressure response to exercise. For cases
in which symptoms for ﬁndings on ECG or exercise test
appear more severe than expected for the estimated
severity by Doppler, cardiac catheterization may be
indicated.
Treatment may be by surgery or balloon aortic valvu-
loplasty. After treatment, patients may be left with
residual valve gradient, aortic insufﬁciency, or both and
may experience recurrence or progression, and thus,
continued clinical follow-up is needed.
Recommendations
1. Athletes with mild AS can participate in all competi-
tive sports (Class I; Level of Evidence B).
2. Athletes with severe AS can participate only in low-
intensity class IA sports (Class I; Level of Evidence B).
3. Athletes with moderate AS may be considered for
participation in low static or low to moderate dynamic
sports (class IA, IB, and IIA) (Class IIb; Level of Evi-
dence B).
4. Athletes with severe AS should be restricted from all
competitive sports, with the possible exception of
low-intensity (class IA) sports (Class III; Level of
Evidence B).
AS After Surgery or Balloon Dilation
Recommendations
1. Athletes with residual AS may be considered for
participation in sports according to the above recom-
mendations based on severity (Class IIb; Level of
Evidence C).
2. Athletes with signiﬁcant (moderate or severe) aortic
valve insufﬁciency may participate in sports according
to the recommendation of Task Force 5 in this docu-
ment (8).
Coarctation of the Aorta: Treated and Untreated
Coarctation may be discrete or in the form of a long
segment and causes hypertension in the upper limbs and
hypotension in the lower limbs. The severity is deter-
mined by a clinical examination that includes the arm/leg
pressure gradient, exercise testing, echocardiographic
studies, and magnetic resonance imaging. Coarctation is
often considered part of a more general aortopathy with a
medial abnormality, particularly when associated witha bicuspid aortic valve. This renders the aorta more
vulnerable to dilation, aneurysm formation, and dissec-
tion and rupture. There is a recognized association with
cerebral aneurysms. Virtually all patients, except those
with mild coarctation, will undergo intervention, in the
form of either surgical repair or percutaneous balloon
angioplasty and stenting.
Even after successful surgical repair or stent place-
ment, residual abnormalities may persist. These include
residual coarctation and aneurysm formation at the site of
repair or stent. Because of the aortopathy, the ascending
aorta may also dilate and even dissect and rupture. Sys-
temic hypertension may persist and if not present at rest
may also occur on exercise. Some patients may have
residual LV hypertrophy, and many may have residual
aortic valve disease when a concomitant bicuspid aortic
valve is present. Lifetime follow-up is mandatory, and the
potential for premature coronary artery disease has been
reported.
Before a decision is made regarding exercise partici-
pation, a detailed evaluation should be conducted, which
should include a physical examination, ECG, chest
radiograph, exercise testing transthoracic echocardio-
graphic evaluation of the aortic valve and aorta, and
either magnetic resonance imaging or computed tomog-
raphy angiography. Normal standards exist for peak sys-
tolic blood pressure on exercise testing, by age and
sex (10,11). Magnetic resonance imaging or computed
tomography imaging should be performed to evaluate the
thoracic aorta in its entirety, because transthoracic
echocardiographic imaging alone will not visualize the
entire aorta, and both residual coarctation and aneurysm
may be missed.Coarctation of the Aorta: Untreated
Recommendations
1. Athletes with coarctation and without signiﬁcant
ascending aortic dilation (z score £3.0; a score of 3.0
equals 3 standard deviations from the mean for
patient size) with a normal exercise test and a resting
systolic blood pressure gradient <20 mm Hg between
the upper and lower limbs and a peak systolic blood
pressure not exceeding the 95th percentile of pre-
dicted with exercise can participate in all competitive
sports (Class I; Level of Evidence C).
2. Athletes with a systolic blood pressure arm/leg
gradient >20 mm Hg or exercise-induced hyperten-
sion (a peak systolic blood pressure exceeding the
95th percentile of predicted with exercise) or with
signiﬁcant ascending aortic dilation (z score >3.0)
may be considered for participation only in low-
intensity class IA sports (Class IIb; Level of
Evidence C).
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2376Coarctation of the Aorta: Treated by Surgery or
Balloon and Stent
Recommendations
1. Athletes who are >3 months past surgical repair or
stent placement with <20 mm Hg arm/leg blood
pressure gradient at rest, as well as (1) a normal ex-
ercise test with no signiﬁcant dilation of the
ascending aorta (z score <3.0), (2) no aneurysm at the
site of coarctation intervention, and (3) no signiﬁcant
concomitant aortic valve disease, may be considered
for participation in competitive sports, but with the
exception of high-intensity static exercise (classes
IIIA, IIIB, and IIIC), as well as sports that pose
a danger of bodily collision (Class IIb; Level of
Evidence C).
2. Athletes with evidence of signiﬁcant aortic dilation or
aneurysm formation (not yet at a size to need surgical
repair) may be considered for participation only in
low-intensity (classes IA and IB) sports (Class IIb;
Level of Evidence C).Elevated Pulmonary Vascular Resistance in CHD
Patients with pulmonary vascular disease and CHD are
at risk of sudden death during sports activity. In those
with shunts (commonly septal defects or complex CHD),
cyanosis is usually present at rest (Eisenmenger syn-
drome) and worsens with exercise. Most of these patients
self-limit their activity, and they should not participate in
competitive sports, with the exception of low-intensity
(class IA) sports. The beneﬁts of a regular exercise pro-
gram, however, including improved walk distance, peak
oxygen consumption, quality of life, and functional class,
have been demonstrated, and thus, physical activity that
does not require maximal effort should be encouraged.
This usually comprises physical activity that allows the
patient to speak a sentence comfortably (the “talk test”),
and 6-minute walk tests will facilitate guidance in
this regard.
Patients with suspected residual pulmonary hyper-
tension who have undergone prior surgical repair or
catheter intervention for shunt lesions should have a
complete hemodynamic evaluation by cardiac catheteri-
zation before engaging in competitive athletics. Pulmo-
nary arterial hypertension is usually deﬁned as a mean
pulmonary artery pressure of >25 mm Hg and a pulmo-
nary arteriolar resistance >3 Wood units. Decisions pro-
scribing exercise for patients with mild degrees of
pulmonary hypertension are quite arbitrary, and no
evidence-based scientiﬁc data exist. Similarly, no data
exist with regard to appropriate exercise prescriptions
for patients with mild and moderate pulmonary hyper-
tension, which emphasizes the need to collect prospec-
tive data.Patients and families should be cautioned, however,
concerning the potential effect of high altitude on the
existing abnormal cardiopulmonary physiology, because
this may lead to important further elevations in pulmo-
nary vascular resistance in such patients, with adverse
effects.
Recommendations
1. Patients with mean pulmonary artery pressure of
<25 mm Hg can participate in all competitive sports
(Class I; Level of Evidence B).
2. Patients with moderate or severe pulmonary hyper-
tension, with a mean pulmonary artery pressure
>25 mm Hg, should be restricted from all competitive
sports, with the possible exception of low-intensity
(class IA) sports. Complete evaluation and exercise
prescription (physician guidance on exercise training)
should be obtained before athletic participation (Class
III; Level of Evidence B).
Ventricular Dysfunction After CHD Surgery
It is not unusual for a patient to present with signiﬁcant
ventricular dysfunction early or late after surgery for
CHD, and this dysfunction, of course, affects exercise
performance. Assessment of ventricular function is more
straightforward for patients with systemic LVs than for
those with systemic RVs, but the use of cardiac magnetic
resonance imaging has improved the assessment of RV
function (12). In general, throughout this document, se-
vere ventricular dysfunction is deﬁned as an ejection
fraction (EF) <40%, moderate dysfunction as EF 40% to
50%, and normal as EF >50%. It should be recognized that
these deﬁnitions are somewhat arbitrary. Of course, the
other characteristics of the patient’s heart disease and
repair should be considered as well, such as valvar
stenosis and insufﬁciency.
Recommendations
1. Before participation in competitive sports, all athletes
with ventricular dysfunction after CHD surgery
should undergo evaluation that includes clinical
assessment, ECG, imaging assessment of ventricular
function, and exercise testing (Class I; Level of
Evidence B).
2. Athletes with normal or near-normal systemic ven-
tricular function (EF ‡50%) can participate in all
sports (Class I; Level of Evidence B).
3. It is reasonable for athletes with mildly diminished
ventricular function (EF 40%–50%) to participate in
low- and medium-intensity static and dynamic sports
(classes IA, IB, and IIA and IIB) (Class IIb; Level of
Evidence B).
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23774. Athletes with moderately to severely diminished
ventricular function (EF <40%) should be restricted
from all competitive sports, with the possible excep-
tion of low-intensity (class IA) sports (Class III; Level
of Evidence B).
Cyanotic CHD, Including Tetralogy of Fallot
Cyanotic Heart Disease: Unoperated or With Palliative Shunts
Patients with congenital defects resulting in chronic
cyanosis can reach adolescence and adulthood but have
signiﬁcantly diminished exercise tolerance, which cor-
relates with clinical outcomes (13–15). Iron deﬁciency
further exacerbates exercise intolerance, whereas select
treatments may improve exercise capacity in this pop-
ulation (16,17). Cardiopulmonary exercise testing shows
that signiﬁcant desaturation occurs in these patients
with exercise, with performance and symptoms related
to underlying anatomy (14,18), including those with
palliative shunts, because of changes in the balance
between pulmonary and systemic vascular resistance.
Full clinical assessment, including laboratory and
exercise testing, should be considered before any
physical activity, because this population represents a
very high risk of sudden death (19). Additional caution
should be taken when these patients are exercising at
altitude (“Elevated Pulmonary Vascular Resistance in
CHD”). Unfortunately, data to address the safety of
participation in competitive sports in this population
are lacking.
Recommendations
1. In athletes with unrepaired cyanotic heart disease, a
complete evaluation is recommended, which should
involve exercise testing. An exercise prescription
based on clinical status and underlying anatomy
should be obtained before athletic participation
(Class I; Level of Evidence C).
2. Athletes with unrepaired cyanotic heart disease who
are clinically stable and without clinical symptoms of
heart failure may be considered for participation in
only low-intensity class IA sports (Class IIb; Level of
Evidence C).
Postoperative Tetralogy of Fallot
Most patients with tetralogy of Fallot currently un-
dergo initial repair in the ﬁrst 2 years of life but often
develop clinically signiﬁcant pulmonary valve dys-
function in adolescence or adulthood. Clinical evalua-
tion of patients before participation in competitive
sports should include assessment of pulmonary valve
function and assessment of factors associated with
increased risk of sudden death in this population
(15,19–21). In particular, attention should be paid tocareful assessment of LV function (13,22). Exercise
testing is recommended to evaluate ability to augment
cardiovascular function during increasing exercise
intensity and for evidence of exercise-related ECG
changes suggestive of arrhythmia or ischemia. Given its
prognostic utility, cardiopulmonary exercise testing
should be considered to fully evaluate patients before
sports participation, particularly those with evidence of
residual lesions on physical examination or imaging
assessment (13,15). We strongly caution against partic-
ipation in high-intensity competitive sports for those
with severe biventricular dysfunction, atrial or ven-
tricular arrhythmias, and signiﬁcant abnormalities on
exercise testing or abnormal hemodynamic assessment.
Evaluation of lung function with pulmonary function
tests may also be useful to assess for evidence of
underlying disease and optimization before sports
participation (23). For participation in moderate- and
high-intensity sports, the patient should be asymp-
tomatic at rest and with exercise, as well as free (or
relatively free) of risk factors associated with sudden
death, although individualized assessment is key for
assessment of additional anatomic anomalies such as
anomalous coronary arteries or residual outﬂow tract
obstruction. Speciﬁc data regarding safety of long-term
high-intensity exercise are needed in tetralogy of Fal-
lot patients with preserved ventricular function with
moderate to severe regurgitation, because a blunted
stroke-volume response with high-intensity exercise
has been reported in this population. One could
extrapolate from these data that exercise performance
in class III sports would be limited, although there
is insufﬁcient evidence to understand cardiovas-
cular risk for these athletes (24). Given this, we
recommend serial clinical evaluation with assessment
of ventricular function during the period of sports
participation.
Recommendations
1. Before participation in competitive sports, it is rec-
ommended that all athletes with repaired tetralogy of
Fallot should undergo evaluation, including clinical
assessment, ECG, imaging assessment of ventricular
function, and exercise testing (Class I; Level of
Evidence B).
2. Athletes without signiﬁcant ventricular dysfunction
(EF >50%), arrhythmias, or outﬂow tract obstruction
may be considered for participation in moderate- to
high-intensity sports (class II to III). To meet these
criteria, the athlete must be able to complete an
exercise test without evidence of exercise-induced
arrhythmias, hypotension, ischemia, or other con-
cerning clinical symptoms (Class IIb; Level of
Evidence B).
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23783. Athletes with severe ventricular dysfunction
(EF <40%), severe outﬂow tract obstruction, or recur-
rent or uncontrolled atrial or ventricular arrhythmias
should be restricted from all competitive sports, with
the possible exception of low-intensity (class IA)
sports (Class III; Level of Evidence B).Transposition of the Great Arteries: After Atrial Switch
(Mustard or Senning Operation)
The atrial switch procedure was reported in 1959 and
was performed frequently for transposition of the great
arteries (TGA) from approximately the 1960s to the
1990s. Thus, the signiﬁcant majority of patients with
this anatomy are adults, because survival into the third
and fourth decades occurs in most patients. Exercise
tolerance is diminished in this population and corre-
lates with clinical outcomes (13,15). Recent studies show
this population may be at higher risk of sudden death
than other CHD populations (19,20). The strongest pre-
dictors of sudden death are the presence of prior
arrhythmia and severe systemic ventricular dysfunction,
although prior VSD, age at repair, QRS duration, and
heart failure symptoms may also be associated with an
increased risk (19,25–29). The population with TGA with
atrial switch likely has a unique response to exercise
given reports that a high proportion of sudden death
events occur during exertion (28). This adds complexity
to the evaluation before sports participation, because
the pathophysiology and prevention strategies for SCD
in this population are not well understood. Unfortu-
nately, evidence of exercise-induced arrhythmias on
routine clinical testing has not been shown to reliably
predict exercise-induced SCD events (28). Thus, careful
evaluation of clinical status with special attention to
clinical history of arrhythmias, patency and structure
of the venous bafﬂes, systemic ventricular function,
coronary artery anatomy, and presence of additional
obstructive lesions (e.g., PS) is recommended. Severe
systemic ventricular function is deﬁned as an EF <40%.
Clinical evaluation should include cardiopulmonary ex-
ercise testing with continuous oximetry before sports
participation. Restriction from high-intensity activities
should be considered in the presence of severe systemic
ventricular dysfunction, persistent arrhythmias, hypox-
ia, or inability to increase cardiac output, blood pres-
sure, or heart rate with exertion. In the absence of
these ﬁndings, moderate-intensity sports participation
may be safe (30). However, the effect of long-term
exercise training on the systemic RV is not known.
Therefore, we recommend serial clinical evaluation
during the period of sports participation, with as-
sessment of ventricular function to evaluate the me-
dium- and long-term effects of exercise participation.Evaluation for and optimization of pulmonary dys-
function are recommended (31).
Recommendations
1. It is recommended that before participation in
competitive sports, all athletes who have undergone
the Senning and Mustard procedure should undergo
an evaluation that includes clinical assessment, ECG,
imaging assessment of ventricular function, and
exercise testing (Class I; Level of Evidence B).
2. Participation in competitive sports in those athletes
with a history of clinically signiﬁcant arrhythmias or
severe ventricular dysfunction may be considered
on an individual basis based on clinical stability
(Class IIb; Level of Evidence C).
3. Athletes without clinically signiﬁcant arrhythmias,
ventricular dysfunction, exercise intolerance, or
exercise-induced ischemia may be considered for
participation in low- and moderate-intensity compet-
itive sports (classes IA, IB, IIA, and IIB) (Class IIb;
Level of Evidence C).
4. Athletes with severe clinical systemic RV dysfunction,
severe RV outﬂow tract obstruction, or recurrent or
uncontrolled atrial or ventricular arrhythmias should
be restricted from all competitive sports, with the
possible exception of low-intensity (class IA) sports.
(Class III; Level of Evidence C).
Congenitally Corrected TGA
Patients with congenitally corrected TGA (CCTGA) are
often diagnosed in childhood, usually in the presence of
additional defects, including PS, VSD, or systemic atrio-
ventricular valve abnormalities (see appropriate sections
for additional recommendations). In CCTGA, exercise
tolerance is limited, and both exercise tolerance and
ventricular function are predictive of adverse outcomes
(13,15,32,33). Systemic atrioventricular valve dysfunction
is not uncommon in this population and correlates with
exercise performance (33). In a recent study, patients with
CCTGA and additional defects were found to have a
particularly high rate of sudden death (19). However,
because of the small number of patients with this anat-
omy, it is difﬁcult to determine the risk factors for this
outcome, although systemic ventricular dysfunction and
arrhythmias may correlate with these events. When
evaluating patients before competitive sports participa-
tion, we recommend assessment of clinical stability with
noninvasive imaging and cardiopulmonary exercise
testing. Clinical assessment should include evaluation of
systemic ventricular and atrioventricular valve function
and coronary artery anatomy, as well as exclusion of
outﬂow tract obstruction. One small study found that
participation of patients with CCTGA in a 3-month
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2379exercise training program of moderate to high intensity
was not associated with clinical decline (30); however,
the effect of long-term exercise training on the systemic
RV is not known. Therefore, we recommend serial
clinical evaluation during the period of sports partici-
pation, with assessment of ventricular function to
evaluate the medium- and long-term effects of exercise
participation.
Limited data are available to assess the risks associated
with sports participation in those who have had a double-
switch procedure that resulted in the redirection of pul-
monary venous blood to the LV and aorta. However,
assessment of the venous bafﬂe and Rastelli or arterial
switch integrity is required before consideration of sports
participation.
Recommendations
1. It is recommended that before participation in
competitive sports, all CCTGA athletes should un-
dergo evaluation that includes clinical assessment,
ECG, imaging assessment of ventricular function, and
exercise testing (Class I; Level of Evidence B).
2. Participation in competitive sports in those CCTGA
athletes with a history of clinically signiﬁcant ar-
rhythmias or severe ventricular dysfunction may be
considered on an individual basis based on clinical
stability (Class IIb; Level of Evidence C).
3. Athletes with CCTGA and without clinically signiﬁcant
arrhythmias, ventricular dysfunction, exercise intol-
erance, or exercise-induced ischemia may be consid-
ered for participation in low- and moderate-intensity
competitive sports (class IA and IB) (Class IIb; Level
of Evidence C).
4. Asymptomatic athletes with CCTGA and without ab-
normalities on clinical evaluation may be considered
for participation in moderate- to high-intensity com-
petitive sports (classes II and IIIB or IIIC) (Class IIb;
Level of Evidence C).
5. Athletes with severe clinical systemic RV dysfunction,
severe RV outﬂow tract obstruction, or recurrent or
uncontrolled atrial or ventricular arrhythmias should
be restricted from all competitive sports, with the
possible exception of low-intensity (class IA) sports
(Class III; Level of Evidence C).
TGA, After Arterial Switch Procedure
Signiﬁcant numbers of patients have now undergone the
arterial switch procedure over the past 3 decades, and
thus, many are at an age when sports participation is
desired. Coronary stenosis or obstruction is fortunately
rare, and concerns are mainly focused on the possibility
of supravalvar PS at the site of anastomosis, which is
rarely signiﬁcant. Patients with symptoms such assyncope or exertional chest pain should have a careful
assessment of their coronary artery status, because
sudden death has been reported late after arterial switch
repair (34). Exercise studies are not particularly sensitive
in this group of patients, and coronary angiography
or other modalities such as computed tomography
angiography may be necessary in those with signiﬁ-
cant symptoms (35). The issue of surveillance of
asymptomatic patients after the arterial switch proce-
dure is controversial.
Recommendations
1. It is recommended that before participation in
competitive sports, athletes who have undergone the
arterial switch procedure for TGA should undergo
evaluation that includes clinical assessment, ECG,
imaging assessment of ventricular function, and
exercise testing (Class I; Level of Evidence B).
2. It is reasonable for athletes with no cardiac symp-
toms, normal ventricular function, and no tachyar-
rhythmias after the arterial switch procedure for TGA
to participate in all competitive sports (Class IIb;
Level of Evidence C).
3. After the arterial switch procedure for TGA, athletes
with more than mild hemodynamic abnormalities
or ventricular dysfunction may be considered for
participation in low and moderate static/low dynamic
competitive sports (classes IA, IB, IC, and IIA), pro-
vided that exercise testing is normal (Class IIb; Level
of Evidence C).
4. After the arterial switch procedure for TGA, athletes
with evidence of coronary ischemia should be
restricted from all competitive sports, with the
possible exception of low-intensity (class IA) sports
(Class III; Level of Evidence B).
Fontan Procedure
The Fontan operation, a complete redirection of sys-
temic venous blood to the pulmonary arteries, is per-
formed to palliate single-ventricle physiology. Patients
with this circulation have signiﬁcantly decreased exer-
cise performance, and they are able to increase cardiac
output during exercise through unique mechanisms
(13,36,37). Limitation to exercise performance is multi-
factorial and correlates with morbidity and mortality
(36,38). When patients are evaluated before sports
participation, it is imperative to recognize that both the
Fontan circulation and the underlying cardiac anatomy
can be extremely variable among patients. As a result,
thorough clinical assessment is recommended before
sports participation. This clinical assessment should
include evaluation for risk factors associated with
sudden death (20,38,39). Additionally, comprehensive
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2380cardiac imaging is recommended, as well as cardiopul-
monary exercise testing with continuous oximetry. If
there is signiﬁcant exercise intolerance during a
maximal effort test, as evidenced by such things as an
inability to increase blood pressure or heart rate, sys-
temic desaturation, or development of arrhythmias or
other symptomatic limitations, the healthcare provider
should strongly consider restriction from participation
in moderate- and high-intensity competitive sports and
training. If the recommended evaluation is unremark-
able, participation in moderate-intensity and moderate-
duration exercise can be considered. This recommen-
dation is based on small studies that have shown evi-
dence of improvement in some measures of ﬁtness
without evidence of clinical deterioration in those
participating in moderate-intensity exercise training
and resistance training (40,41). However, the safety of
participation in high-intensity or high-duration sports is
unknown. Additionally, evaluation and optimization of
lung function before sports participation is recom-
mended (42). All Fontan patients requiring chronic
anticoagulation should be restricted from participation
in contact sports.
Recommendations
1. It is recommended that before participation in
competitive sports, all athletes who have undergone
the Fontan procedure should undergo an evaluation
that includes clinical assessment, ECG, imaging
assessment of ventricular function, and exercise
testing (Class I; Level of Evidence B).
2. Athletes who have undergone the Fontan procedure and
who have no symptomatic heart failure or signiﬁcantly
abnormal intravascular hemodynamics can participate
only in low-intensity class IA sports (Class I; Level of
Evidence C).
3. Participation in other sports may be considered on an
individual basis with regard for the athlete’s ability to
complete an exercise test without evidence of
exercise-induced arrhythmias, hypotension, ischemia,
or other concerning clinical symptoms (Class IIb; Level
of Evidence C).
Ebstein Anomaly of the Tricuspid Valve
The phenotypic spectrum of this malformation is
extreme, ranging from minimal to profound tricuspid
regurgitation and right-sided heart enlargement. If there
is an atrial shunt, cyanosis may be present. A minority of
patients with Ebstein anomaly will have preexcitation
that could precipitate clinically important and symptom-
atic arrhythmias. Physical disability and increased risk
for sudden death with exercise have been reported
with severe cases. Risk stratiﬁcation for exercise-relatedarrhythmias remains imprecise for this anomaly. In
patients for whom there is also evidence of Wolff-
Parkinson-White syndrome or in whom a deﬁbrillator
has been implanted, the recommendations found in
Task Force 9 (43) should be respected as well. Note that
the recommendations below apply both before and after
surgical plication and are based on the degree of valve
regurgitation and existence of arrhythmias.Recommendations
1. Patients with mild to moderate Ebstein anomaly (i.e.,
no cyanosis, normal RV size, tricuspid regurgitation
that is moderate or less, and no evidence of atrial or
ventricular arrhythmias) can be considered for partic-
ipation in all sports (Class IIb; Level of Evidence C).
2. Patients with Ebstein anomaly with severe tricuspid
regurgitation but without evidence of arrhythmias on
ambulatory electrocardiographic monitoring (except
isolated premature contractions) may be considered
for participation only in low-intensity class IA sports
(Class IIb; Level of Evidence C).
Congenital Coronary Anomalies
Anomalies of coronary arteries are second in frequency
among identiﬁed structural causes of SCD in competi-
tive athletes, accounting for z17% of such deaths in the
United States (44). Anomalous origins of coronary ar-
teries from the wrong sinus of Valsalva or from the
pulmonary artery are estimated to be present in z1%
of the overall population (45) but are proportionately
far more common in athletes who die suddenly, as cited
above. Although the vast majority of sudden deaths
associated with coronary anomalies occur during or
shortly after exercise (46), sudden death has been
reported in the sedentary state (47).
The most common anomalous origin is the right
coronary artery originating from the left sinus of Val-
salva, but among athletes who have died suddenly,
anomalous origin of the left main or left anterior
descending coronary artery from the right sinus of
Valsalva is far more prevalent. Furthermore, SCDs are
most strongly associated with the pattern in which the
anomalous left coronary artery passes between the aorta
and main pulmonary artery. An anomalous origin of a
coronary artery from the pulmonary artery is far less
commonly observed in athletes who die suddenly and
in fact often presents with myocardial infarction in in-
fancy or early childhood. Nonetheless, some cases are
not recognized until adolescence or adulthood and may
be associated with sudden death in athletes, albeit
rarely. Nonspeciﬁc electrocardiographic ﬁndings may be
observed in adolescents with otherwise unrecognized
anomalous coronary arteries arising from the pulmonary
artery.
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2381The ECG is an unreliable screening tool for suspect-
ing or recognizing anomalous origin of coronary ar-
teries before an event, and even stress tests are not
uniformly positive among people with these anomalies
(48). Clinical symptoms, such as exertional chest
discomfort or dyspnea, may be helpful, but 2 reports
suggest that 50% of SCDs associated with coronary ar-
tery anomalies were ﬁrst events without prior symp-
toms (46,49). The best methods for identifying the
anomaly include coronary angiography, computed to-
mography angiography, and magnetic resonance angi-
ography. Although not uniformly successful, athletes
undergoing echocardiographic studies for any reason
should have careful attempts to identify the origins of
the coronary arteries.
Surgical procedures are the only therapies available for
correcting these anomalies (50), with return to intense
athletic activities permitted after 3 months after the pro-
cedure with demonstration of the absence of ischemia
on postoperative stress testing (51).
Recommendations
1. Athletes with anomalous origin of a coronary ar-
tery from the pulmonary artery can participate
only in low-intensity class IA sports, whether or
not they have had a prior myocardial infarction,
and pending repair of the anomaly (Class I; Level
of Evidence C).
2. Athletes with an anomalous origin of a right coronary
artery from the left sinus of Valsalva should be eval-
uated by an exercise stress test. For those without
either symptoms or a positive exercise stress test,
permission to compete can be considered afteradequate counseling of the athlete and/or the ath-
lete’s parents (in the case of a minor) as to risk and
beneﬁt, taking into consideration the uncertainty of
accuracy of a negative stress test (Class IIa; Level of
Evidence C).
3. After successful surgical repair of an anomalous origin
from the wrong sinus, athletes may consider partici-
pation in all sports 3 months after surgery if the
patient remains free of symptoms and an exercise
stress test shows no evidence of ischemia or cardiac
arrhythmias (Class IIb; Level of Evidence C).
4. After repair of anomalous origin of a coronary artery
from the pulmonary artery, decisions regarding exer-
cise restriction may be based on presence of sequelae
such as myocardial infarction or ventricular dysfunc-
tion (Class IIb; Level of Evidence C).
5. Athletes with an anomalous origin of a left coronary
artery from the right sinus of Valsalva, especially
when the artery passes between the pulmonary
artery and aorta, should be restricted from partici-
pation in all competitive sports, with the possible
exception of class IA sports, before surgical repair.
This recommendation applies whether the an-
omaly is identiﬁed as a consequence of symptoms
or discovered incidentally (Class III; Level of
Evidence B).
6. Nonoperated athletes with an anomalous origin of a
right coronary artery from the left sinus of Valsalva
who exhibit symptoms, arrhythmias, or signs of
ischemia on exercise stress test should be restricted
from participation in all competitive sports, with the
possible exception of class IA sports, before a surgical
repair (Class III; Level of Evidence C).
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